Pharmaceutical Company Announces New Patent Application For Metabolic Syndrome Treatment

SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies for disorders and rare diseases of the central nervous system, has recently announced that it has submitted an additional patent application to the United States Patent and Trademark Office (USPTO). This submission is part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotech company known for its development of novel psychedelic-derived therapeutics. $Clearmind Medicine (CMND.US)$